Skip to main content

Health and digital technology have not only converged, they have united into a powerful force that has sparked a fundamental shift in the way people manage their health and access medical care.

Abbott’s best-in-class portfolio of biowearable technologies is helping to drive this movement. This portfolio includes continuous glucose monitoring technology – the FreeStyle Libre system – and future technology still in development, including a continuous glucose and ketone monitoring system for people with diabetes and a new category of large biowearables. public for people without the chronic condition.

We spoke to Jared Watkin, senior vice president of Abbott’s diabetes care business, about the FreeStyle Libre system – the technology that laid the foundation for the company’s biosensor innovations – what’s next stage for this portfolio, how it is driving the future of biowearables and what the future might look like.

What makes the FreeStyle Libre wallet different from other CGM technologies on the market?

The design approach we took from day one. We wanted to make a continuous glucose sensor as affordable as possible and bring it to market so it could reach far more people than the technology had ever reached before. And that’s the case. Today, more than 4 million people in over 60 countries use the FreeStyle Libre system.

How do you keep the FreeStyle Libre system accessible and affordable?

The 14-day sensor life is critical. The longer the sensor lasts, the fewer sensors a person has to buy and the more affordable the technology is on a monthly basis. We also spent a lot of time making sure the sensor was easy to apply and wear, and the system user interface was simple for people who use it every day.

How does the FreeStyle Libre portfolio impact your latest innovations in biosensor technology?

When we created FreeStyle Libre technology, we always knew it could be used for more than glucose and could go beyond people with diabetes. Glucose was our focus and will remain a major focus for us, but now we’re expanding that platform to more people. We take the expertise that comes from having over 4 million people using our technology and build on it.

We are currently developing a dual sensor that will allow people with diabetes to continuously measure both glucose and ketones in the same sensor. And we are developing Lingo, our line of consumer biowearables, which will provide people with real-time data, personalized information, education and resources.

Complete this sentence: The convergence of health technologies is… Make health more accessible to more people. This gives them easy-to-understand information about their bodies and gives them more freedom and control over their health and day-to-day decisions.

What is the future of FreeStyle Libre technology?

We’re innovating next-generation technology to continue helping people with type 1 and type 2 diabetes better manage their condition. We also see interest in using our technology to measure analytes beyond glucose – ketones, lactate and alcohol – in people who do not have diabetes.

In 10 years, where will biosensor technology be?

Help optimize the treatment of chronic conditions beyond diabetes and empower people with personalized insights to improve their health outcomes. I think this technology will move into wellness, helping people slow down pre-diabetes and, in some cases, prevent diabetes. We will treat for health rather than disease.